Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
Holding YMAB?
Track your performance easily
See the Price Targets and Ratings of:
YMAB Analyst Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
YMAB Stock 12 Month Forecast
Average Price Target
$31.20
▲(140.37% Upside)
| Highest Price Target$64.00 | Average Price Target$31.20 | Lowest Price Target$21.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JonesTrading
Initiated
07/11/24
Truist Financial
Initiated
06/28/24
Bank of America Securities
Reiterated
05/10/24
H.C. Wainwright
Reiterated
05/10/24
Canaccord Genuity
Reiterated
05/07/24
BMO Capital
$26
Buy
100.31%
Upside
Reiterated
04/05/24
BMO Capital on Y-mAbs Therapeutics (YMAB): Radiopharma Is Hot SADA De-Risking Would Unlock ValueBMO Capital analyst Etzer Darout reiterated an Outperform rating and $26.00 price target on Y-mAbs Therapeutics (NASDAQ: YMAB)
Wedbush
$12→$18
Buy
38.67%
Upside
Reiterated
02/12/24
Y-mAbs Therapeutics (YMAB) PT Raised to $18 at WedbushWedbush analyst David Nierengarten raised the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $18.00 (from $12.00) while maintaining a Outperform rating.
J.P. Morgan
$8→$7
Sell
-46.07%
Downside
Reiterated
08/22/23
Y-mAbs Therapeutics price target lowered to $7 from $8 at JPMorganY-mAbs Therapeutics price target lowered to $7 from $8 at JPMorgan
Morgan Stanley
$7→$5
Sell
-61.48%
Downside
Reiterated
08/14/23
Y-mAbs Therapeutics price target lowered to $5 from $7 at Morgan StanleyY-mAbs Therapeutics price target lowered to $5 from $7 at Morgan Stanley
Best Analysts Covering Y-Mabs Therapeutics
Which Analyst Should I Follow If I Want to Buy YMAB and Sell After:
1 Month
xxx
Success Rate
6/13 ratings generated profit
Average Return
+0.78%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.15% of your transactions generating a profit, with an average return of +0.78% per trade.
3 Months
xxx
Success Rate
4/9 ratings generated profit
Average Return
+1.09%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +1.09% per trade.
1 Year
Success Rate
8/12 ratings generated profit
Average Return
+66.19%
reiterated a buy rating 8 months ago
Copying William Maughan's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +66.19% per trade.
2 Years
xxx
Success Rate
9/12 ratings generated profit
Average Return
+82.15%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +82.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
YMAB Analyst Recommendation Trends
Rating
Mar 24
Apr 24
May 24
Jun 24
Jul 24
Strong Buy
4
2
4
4
4
Buy
4
4
2
0
0
Hold
1
0
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
6
7
5
5
Each month's total comprises the sum of three months' worth of ratings.
YMAB Financial Forecast
YMAB Stock Forecast FAQ
What is YMAB’s average 12-month price target, according to analysts?
Based on analyst ratings, Y-Mabs Therapeutics’s 12-month average price target is $31.20.
What is YMAB’s upside potential, based on the analysts’ average price target?
Y-Mabs Therapeutics has 140.37% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is YMAB a Buy, Sell or Hold?
Y-Mabs Therapeutics has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
What is Y-Mabs Therapeutics’s price target?
The average price target for Y-Mabs Therapeutics is $31.20. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $64.00 ,the lowest forecast is $21.00. The average price target represents 140.37% Increase from the current price of $12.98.
The highest analyst price target is $64.00 ,the lowest forecast is $21.00. The average price target represents 140.37% Increase from the current price of $12.98.
What do analysts say about Y-Mabs Therapeutics?
Y-Mabs Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of YMAB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.